MENLO PARK, Calif.--(BUSINESS WIRE)--Avellino Lab USA, Inc. (Avellino) is pleased to announce Jon Robson as the company’s new CEO and member of the Board of Directors. Jon replaces former Avellino CEO Jim Mazzo, as Jim has transitioned to an advisory role for the company.
Jon will lead the company’s next phase of innovation and growth, including further integrating Avellino’s depth of genetic expertise with machine learning, AI, and big data. This impactful combination will help the company continue to develop life-changing diagnostics and therapeutics that help improve patient outcomes, along with curating a diverse genetic database.
“The Board of Directors and I are thrilled to welcome Jon to the Avellino team and are confident he is the right leader to help usher in our next chapter of growth. This chapter leans heavily into leveraging the latest technologies to advance our pipeline of genetic-based diagnostics and therapies, which will be fueled by the development of a diverse and robust genetic database,” says Avellino Founder and Chairman Gene Lee.
He continues, “Jon has deep experience in identifying market opportunities and leading high-performing organizations, along with strong technical acumen, and I greatly look forward to partnering with him during this exciting time for the entire Avellino team. I also want to take this time to thank Jim Mazzo for his tremendous leadership and I greatly look forward to partnering with him in his new role as senior advisor.”
“Avellino has a truly innovative approach to solving some of the most significant challenges in health,” shares Jon Robson. “By combining extraordinary knowledge of the human genome with the latest in technology, including machine learning and AI, the company is on an exciting path of developing diagnostics and therapies that will transform lives. I am truly excited to join as CEO and to help contribute to improving health globally.”
Jon has highly relevant experience in creating value from data and analytics with both early-stage technology companies and large multinational data businesses. Jon was founder and CEO of MoneyLine Telerate, CEO of Reuters Americas, President of Thomson Reuters Enterprise Division, CEO of NYSE Technologies, President of First Derivatives plc, and President of DXC Luxoft‘s Capital Markets division.
Former CEO Jim Mazzo states, “It has been an honor and pleasure to serve Avellino. I look forward to continuing to support the company in an advisory role, and I wish Jon every success as he leads Avellino in its next phase of growth.”
About Avellino
Avellino Lab USA, Inc. is a global leader in gene therapy and molecular diagnostics at the forefront of precision medicine for eye care. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as genetic therapeutics leveraging CRISPR gene editing, to better manage, and potentially cure, inherited diseases. The company also developed the Avellino SARS-CoV-2 RT-PCR diagnostic test to aid in COVID-19 pandemic testing efforts in the US, and was the third private company in the US to receive EUA for its COVID-19 test. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, China and the UK.
To learn more about Avellino, visit www.avellino.com.
